102 related articles for article (PubMed ID: 3663521)
1. Cell kinetic effect of low dose arabinosyl cytosine.
Baccarani M; Tazzari PL; Motta MR; Rizzi S; Fanin R; Fasola G; Damiani D; Dinota A; Tura S
Br J Haematol; 1987 Sep; 67(1):33-7. PubMed ID: 3663521
[TBL] [Abstract][Full Text] [Related]
2. In vitro exposure of leukemic cells to low concentration Arabinosyl Cytosine: no evidence of differentiation inducing activity.
Motta MR; Baccarani M; Rizzi S; Fanin R; Fasola G; Poluzzi C; Tura S
Blut; 1987 May; 54(5):299-306. PubMed ID: 3567369
[TBL] [Abstract][Full Text] [Related]
3. Arabinosyl cytosine in chronic myeloid leukaemia: evidence for high cytokinetic sensitivity of myeloblasts.
Baccarani M; Santucci AM; Tura S; Killmann SA
Scand J Haematol; 1976 May; 16(5):335-52. PubMed ID: 1065953
[TBL] [Abstract][Full Text] [Related]
4. [Effect of modified FLAG regimen therapy on 33 patients with relapsed/refractory leukemia].
Meng FY; Yang LJ; Xu B; Liu XL; Zheng WY; Zhang Y; Huang F; Sun J; Liu QF
Ai Zheng; 2003 Dec; 22(12):1330-3. PubMed ID: 14693062
[TBL] [Abstract][Full Text] [Related]
5. Biochemical pharmacology of high dose 1-beta-D-arabinofuranosylcytosine in childhood acute leukemia.
Avramis VI; Biener R; Krailo M; Finklestein J; Ettinger L; Willoughby M; Siegel SE; Holcenberg JS
Cancer Res; 1987 Dec; 47(24 Pt 1):6786-92. PubMed ID: 3479250
[TBL] [Abstract][Full Text] [Related]
6. Low-dose arabinosyl cytosine therapy of AML may be effective after failure of high or conventional doses.
Tertian G; Tchernia G; Léonard C; Miélot F; Avalos M; Mirica C; Brivet F; Dommergues JP
Nouv Rev Fr Hematol (1978); 1989; 31(4):311-3. PubMed ID: 2608442
[TBL] [Abstract][Full Text] [Related]
7. Low-dose arabinosyl cytosine in acute leukemia after a myelodysplastic syndrome and in elderly leukemia.
Alessandrino EP; Orlandi E; Brusamolino E; Lazzarino M; Bernasconi C
Am J Hematol; 1985 Oct; 20(2):191-3. PubMed ID: 4036958
[TBL] [Abstract][Full Text] [Related]
8. Cellular and clinical pharmacology of low-dose ara-C.
Kufe DW; Griffin JD; Spriggs DR
Semin Oncol; 1985 Jun; 12(2 Suppl 3):200-7. PubMed ID: 3925558
[TBL] [Abstract][Full Text] [Related]
9. The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukaemia in relapse.
van Prooijen HC; Dekker AW; Punt K
Br J Haematol; 1984 Jun; 57(2):291-9. PubMed ID: 6733049
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy for acute non-lymphocytic leukemia with low-dose cytosine arabinoside (Ara-C).
Lin SF; Liu HW; Chen TP
Nihon Ketsueki Gakkai Zasshi; 1990 Feb; 53(1):45-50. PubMed ID: 2330805
[TBL] [Abstract][Full Text] [Related]
11. Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside.
Preisler HD; Epstein J; Barcos M; Priore R; Raza A; Browman GP; Vogler R; Winton E; Grunwald H; Rai K
Br J Haematol; 1984 Sep; 58(1):19-32. PubMed ID: 6466567
[TBL] [Abstract][Full Text] [Related]
12. Low dose cytosine arabinoside in the treatment of acute non-lymphocytic leukaemia.
Jensen MK; Ahlbom G
Scand J Haematol; 1985 Mar; 34(3):261-3. PubMed ID: 3992192
[TBL] [Abstract][Full Text] [Related]
13. The effect of low dose Ara-C in acute nonlymphoblastic leukaemias and atypical leukaemia.
Ishikura H; Sawada H; Okazaki T; Mochizuki T; Izumi Y; Yamagishi M; Uchino H
Br J Haematol; 1984 Sep; 58(1):9-18. PubMed ID: 6466575
[TBL] [Abstract][Full Text] [Related]
14. In vivo differentiation of leukaemic blasts and effect of low dose Ara-C in a marrow grafted patient with leukaemic relapse.
Mittermüller J; Kolb HJ; Gerhartz HH; Wilmanns W
Br J Haematol; 1986 Apr; 62(4):757-62. PubMed ID: 2938618
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic results of DCMP therapy (2M-80) in acute non-lymphocytic leukemia--the relationship between the residual leukemic cells and duration of remission].
Moriyama Y; Urushiyama M; Ohnishi M; Koyama S; Hirosawa H; Hanano M; Fuse I; Takai K; Nagayama R; Fujiwara M; Kishi K; Takahashi M; Koike T; Sakai C; Kashimura M; Miura R; Aoyagi A; Sanada M; Hattori A; Shibata A; Shinada S
Gan To Kagaku Ryoho; 1982 Sep; 9(9):1549-54. PubMed ID: 6892201
[TBL] [Abstract][Full Text] [Related]
16. [The clinical effect of low-dose Ara-C in patients with refractory acute nonlymphocytic leukemia and myelodysplastic syndrome].
Yoshida M; Tsunoda S; Akutsu M; Furukawa Y; Takeda K; Akashi M; Komatsu N; Muroi K; Ikeda K; Ohsaka A
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1057-62. PubMed ID: 3566302
[TBL] [Abstract][Full Text] [Related]
17. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
Nowrousian MR; Seeber S; Miller AA; Anders C; Ohl S; Schmidt CG
Onkologie; 1985 Feb; 8(1):26-32. PubMed ID: 3885117
[TBL] [Abstract][Full Text] [Related]
18. Low-dose cytosine arabinoside in the treatment of relapsed and refractory acute non-lymphocytic leukaemia.
Krogh Jensen M; Stentoft J
Acta Haematol; 1986; 76(2-3):127-9. PubMed ID: 3101350
[TBL] [Abstract][Full Text] [Related]
19. High-dose cytosine arabinoside as the initial treatment of poor-risk patients with acute nonlymphocytic leukemia: a Leukemia Intergroup Study.
Preisler HD; Raza A; Barcos M; Azarnia N; Larson R; Walker I; Browman M; Grunwald H; D'Arrigo P; Doeblin T
J Clin Oncol; 1987 Jan; 5(1):75-82. PubMed ID: 3806162
[TBL] [Abstract][Full Text] [Related]
20. Low-dose Ara-C can cause complete remission of acute non-lymphocytic leukemia: differentiation induction?
Ye JS; Feng GH; Liang GR; Tao MX
Leuk Res; 1986; 10(10):1221-4. PubMed ID: 3773565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
